218 patents
Page 5 of 11
Utility
Heterocyclic compounds as LSD1 inhibitors
2 Aug 22
Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
Filed: 28 Aug 20
Utility
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
2 Aug 22
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 29 Sep 20
Utility
Pyrimidinones as PI3K inhibitors
2 Aug 22
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
Filed: 30 Sep 20
Utility
Substituted heterocyclic derivatives as PI3K inhibitors
26 Jul 22
Stacey Shepard, Andrew P. Combs
Filed: 12 Nov 19
Utility
Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
19 Jul 22
Taisheng Huang, Xiaozhao Wang
Filed: 28 Jan 20
Utility
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
12 Jul 22
Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao
Filed: 14 Feb 20
Utility
Crystalline solid forms of a BET inhibitor
5 Jul 22
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 18 Dec 20
Utility
Pyridine and pyridimine compounds as PI3K-gamma inhibitors
7 Jun 22
Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
Filed: 29 Mar 19
Utility
Sustained-release dosage forms of ruxolitinib
24 May 22
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 16 Nov 20
Utility
Heterocyclic compounds as immunomodulators
24 May 22
Liangxing Wu, Jingwei Li, Wenqing Yao, Chao Qi, Ding-Quan Qian, Fenglei Zhang
Filed: 18 Aug 20
Utility
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
17 May 22
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 17 Mar 20
Utility
Combination therapy for treatment of hematological diseases
10 May 22
The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.
Albert Assad
Filed: 31 Oct 19
Utility
Treatment of hidradenitis suppurativa using JAK inhibitors
19 Apr 22
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
Michael D. Howell, Paul Smith
Filed: 29 Mar 19
Utility
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
19 Apr 22
Artem Shvartsbart, Andrew P. Combs, Nikoo Falahatpisheh, Padmaja Polam, Lixin Shao, Stacey Shepard
Filed: 20 Dec 18
Utility
Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
29 Mar 22
The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Taisheng Huang, Chu-Biao Xue
Filed: 19 May 20
Utility
Low dose combination therapy for treatment of myeloproliferative neoplasms
22 Mar 22
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.
Holly Koblish, Gary Reuther
Filed: 6 Feb 20
Utility
Imidazotriaines and imidazopyrimidines as kinase inhibitors
1 Mar 22
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
Filed: 23 Jun 20
Utility
Cyclopropylamines as LSD1 inhibitors
15 Feb 22
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Liangxing Wu, Joel R. Courter, Chunhong He, Xiaozhao Wang, Wenqing Yao, Fenglei Zhang
Filed: 9 Jun 20
Utility
Formulations of an AXL/MER inhibitor
8 Feb 22
The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.
William L. Rocco, Francis X. Muller
Filed: 28 Jun 19
Utility
Pyrazolopyridine compounds and uses thereof
8 Feb 22
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 10 Feb 20